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We evaluated leukocyte counts and levels of CRP, ﬁbrinogen, MPO, and PAPP-A in patients with stable and unstable angina
pectoris, acute myocardial infarction, and healthy controls. All biomarkers were analyzed again after 6 months. Leukocyte counts
andconcentrationsofﬁbrinogen,CRP,MPO,andPAPP-Aweresigniﬁcantlyincreasedinpatientswithacutemyocardialinfarction.
Leukocyte counts and concentrations of MPO were signiﬁcantly increased in patients with unstable angina pectoris compared
with controls. After 6 months, leukocyte counts and MPO concentrations were still increased in patients with acute myocardial
infarction when compared to controls. Discriminant analysis showed that leukocyte counts, MPO, and PAPP-A concentrations
classiﬁed study group designation for acute coronary events correctly in 83% of the cases. In conclusion, combined assessment of
leukocyte counts, MPO, and PAPP-A was able to correctly classify acute coronary events, suggesting that this could be a promising
panel for a multibiomarker approach to assess cardiovascular risk.
1.Introduction
Atherosclerosis is an inﬂammatory disease of the large arter-
ies that is characterized by the formation of atherosclerotic
plaques. In the majority of cases, atherosclerosis-related
clinical events, like myocardial infarction or ischemic stroke,
are caused by rupture of a vulnerable atherosclerotic lesion
[1–3].
Several inﬂammatory molecules have been put forward
as biomarkers for plaque vulnerability. Biomarkers are
biochemical features that can be used to measure the
presence of a certain disease, the disease progress, or the
eﬀect of treatment [4]. In the context of atherosclerosis,
concentrations of C-reactive protein (CRP) and ﬁbrinogen
and the count of leukocytes in blood have been investigated
most extensively [5–7]. However, large meta-analyses have
demonstrated that their prognostic value for assessing risk
of cardiovascular disease or adverse outcomes is limited [7–
10]. Therefore, there is a continuous search for novel, more
powerful biomarkers that are able to predict the occurrence
of future cardiovascular complications.
Until now, no single biomarker has been able to accu-
rately predict the risk of near-future cardiovascular events
in the individual patient. The general opinion is therefore
shifting towards a so-called “multi-biomarker” approach, in
which a certain panel of biomarkers is assessed to determine
an individual risk proﬁle of a patient for cardiovascular
disease [4]. However, it remains unclear which biomarkers
should be included in this panel.
Our study aim was to assess levels of selected biomark-
ers simultaneously in several groups of patients with2 International Journal of Vascular Medicine
cardiovascular disease. We focused on leukocyte counts and
concentrations of ﬁbrinogen, CRP, MPO, and PAPP-A, as
these biomarkers have been studied extensively in large
cohorts (leukocyte counts, ﬁbrinogen, CRP [7–10]) or have
shown potential in smaller cohorts (MPO, PAPP-A [11–13]).
Inaddition,weinvestigatedthelevelsoftheseﬁvebiomarkers
after 6-month followup to evaluate changes in this period,
and we used a stepwise discriminate analysis to investigate
which of the currently tested biomarkers might be most
appropriate to include in a “multi-biomarker” panel.
2.MaterialsandMethods
For this study, the total study cohort consisted of 120
patients, who were divided into four study groups: stable
anginapectoris(SAP),unstableanginapectoris(UAP),acute
myocardial infarction (AMI), and healthy controls (CON).
Venous blood samples were drawn from all participants at
inclusion and after 6-month followup. Also, a standardized
questionnaire regarding patient characteristics, risk factors,
and followup outcome (such as the occurrence of new
or recurrent clinical events) was presented at study inclu-
sion and followup. Medication use was assessed during
study inclusion and included beta-blockers, oral nitrates,
ACE inhibitors, statins, ﬁbrates, calciumantagonists, insulin,
aspirin, hormone replacement therapy, and antidiabetics.
The study protocol was approved by the institutional med-
ical ethics committee. All patients gave written, informed
consent prior to study inclusion. The funders had no role
in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
PatientswithSAPthatwerescheduledforapercutaneous
coronary intervention were recruited from the outpatient
clinic. Only patients with more than 50% stenosis of one
or more of the main coronary branches (as proven by
coronary angiography) were included. Evaluation of the
coronary stenosis was performed by cardiologists blinded
for study aims. Patients with UAP presented themselves with
p r o l o n g e dn e w - o n s e tc h e s tp a i n( <30 days), an accelerating
pattern of chest pains or with chest pains occurring at
lesser degrees of exertion or at rest. UAP was characterized
by ischemic ECG changes (such as ST segment elevation,
reciprocal ST segment depression, T wave inversion, or
development of Q waves) without elevation of cardiac
enzymes (such as troponin-T, creatine kinase, and lactate
dehydrogenase isozymes) or by elevation of cardiac enzymes
without apparent ischemic ECG changes. Patients with AMI
presented themselves with an acute onset of chest pain,
ischemic ECG changes, and elevation of cardiac enzymes
and troponin T. Diagnoses of UAP or AMI were made by
cardiologists blinded for the study aims. The control group
consisted of individuals of the general population older
than 45 years, but free of cardiovascular disease and serious
illnesses for the past 6-month.
In all groups, exclusion criteria were inability to provide
informed consent, recent acute coronary event, stroke or
transient ischemic attack (all events less than 6-month prior
to study inclusion), history of resuscitation or cardiogenic
shock, renal insuﬃciency (creatinine clearance <40mL/min
according to the Cockroft formula [14]), current inﬂamma-
tory disease, autoimmune diseases, and the presence of a
disorder with a high chance of death within 5 years (e.g.,
malignancies).
Blood samples were drawn from the antecubal vein. In
patients with SAP, blood sampling was performed imme-
diately prior to percutaneous coronary intervention. In
patients with UAP and AMI, blood was drawn and processed
within 12 hours after the last ischemic episode and before
intervention. Levels of ﬁbrinogen, total cholesterol, HDL-
C, LDL-C, liver function enzymes (AST, ALT), creatine
kinase, creatinine, and leukocyte counts were determined
with standard hospital laboratory assays. The blood samples
used for the determination of CRP, PAPP-A, and MPO were
centrifuged immediately after sampling and frozen at −80
◦C
until assays were performed. All samples were thawed only
once. By using coded samples, all laboratory analyses were
performed blinded for study group designation.
Enzyme-linked immunosorbent assays (ELISA) were
performed to determine serum levels of CRP (Kordia,
Leiden, The Netherlands), PAPP-A, and MPO (all DRG
Instruments GmbH, Germany). In addition, a new ultra-
sensitive assay kit for PAPP-A (PAPP-A US) was used. This
was a research kit from DRG Instruments, which uses a
monoclonalantibodyspeciﬁcforpatientswithAMI,whereas
the regular kit uses a polyclonal antibody. Assays were
performed according to the instructions provided by the
manufacturer. Assay ranges were 1–25mg/L for CRP, 0–
30µg/l for PAPP-A, and 0–450µg/L for ultra-sensitive PAPP-
A. For MPO, the detection limit was <3µg/L.
2.1. Statistical Analysis. Statistical analysis was carried out
with SPSS 15.0 (Chicago, USA). Since the distribution
of biomarker levels was slightly skewed, statistical tests
were performed on logarithmically transformed biomarker
values, while mean (arithmetic) values of these values were
presented. Depending on the research questions and the
outcomevariables,threediﬀerenttestswereapplied.First,an
univariate analysis of variance (ANOVA) was used to deter-
mine which variables were signiﬁcantly associated with the
biomarkers baseline measurements. Multicollinearity among
explanatory variables (see also Table 1) was checked via the
variance inﬂation factor and a top-down procedure was used
to determine the ﬁnal model parameters. For all models,
the group’s eﬀect on the individual biomarkers was adjusted
for sex, smoking, family history of cardiovascular disease,
daily aspirin use, and exercise (deﬁned as a signiﬁcant
increase in heart rate for more than 30 minutes per week),
since these proved to be relevant parameters that needed to
be included in the ﬁnal model. Additional adjustment for
age and renal clearance was performed in the analysis of
ﬁbrinogen and PAPP-A concentrations, and for body mass
index in the analysis of CRP. All other patient characteristics
as noted in the questionnaires proved to be nonrelevant
model parameters and as such, were not included in the
statistical analysis. Adjusted post-hoc groups comparisons
werecarriedoutusingtheBonferronicorrectionformultipleInternational Journal of Vascular Medicine 3
Table 1: Baseline patient characteristics per study group.
SAP UAP AMI CON P-value
Total participants 30 30 30 30
Age (mean years ± SD) 63.6 (10.5) 65.3 (13.0) 59.5 (12.6) 65.0 (9.5) NS
Male (%) 28 (93.3) 16 (55.1) 24 (80.0) 19 (63.3) .004
Smoking (%) 7 (23.3) 5 (16.7) 13 (43.3) 4 (13.3) .034
Exercise (%) 14 (46.7) 15 (50.0) 8 (26.7) 22 (73.3) .004
Alcohol use (U/day ± SD) 0.7 (1.3) 0.4 (0.7) 0.5 (0.9) 1.3 (1.1) NS
Family history for CVD (%) 26 (86.7) 18 (60.0) 14 (46.7) 19 (63.3) .013
Diabetes (%) 3 (10.0) 7 (23.3) 1 (3.3) 3 (10.0) NS
Beta-blocker use (%) 30 (100.0) 15 (50.0) 12 (40.0) 5 (16.7) <. 001
Statin use (%) 26 (86.7) 18 (60.0) 12 (40.0) 6 (20.0) <. 001
Aspirin use (%) 13 (43.3) 14 (46.7) 12 (40.0) 1 (3.3) .001
Antidiabetica use (%) 2 (6.7) 5 (16.7) 1 (3.3) 3 (10.0) NS
Cholesterol level (mmol/L ± SD) 4.2 (1.0) 4.7 (1.3) 5.5 (1.1) 5.6 (1.3) <. 001
HDL-C (mmol/L ± SD) 1.1 (0.2) 1.0 (0.2) 1.0 (0.2) 1.2 (0.4) NS
LDL-C (mmol/L ± SD) 2.1 (1.0) 3.0 (1.1) 3.9 (1.0) 3.6 (1.1) <. 001
ALT (IU/L± SD) 34 (17) 31 (19) 37 (22) 26 (29) NS
AST (IU/L± SD) 26 (13) 30 (16) 99 (139) 22 (11) NS
Renal clearance (mL/min ± SD) 85.8 (29.7) 83.7 (28.2) 93.2 (20.1) 83.7 (26.4) NS
Systolic BP (mmHg ± SD) 131.0 (14.8) 141.3 (22.0) 129.7 (30.0) 132.2 (15.6) NS
Diastolic BP (mmHg ± SD) 76.6 (7.9) 77.5 (15.3) 73.8 (15.4) 82.8 (8.6) .001
Body mass index (kg/m2± SD) 26.4 (3.7) 25.8 (2.9) 27.1 (3.5) 26.4 (3.9) NS
Troponin-T (µg/L ± SD) 0.00 (0.00) 0.21 (0.13) 2.08 (0.73) 0.00 (0.00) .003
Creatine kinase (U/L) 154.0 (107.5) 148.3 (141.3) 639.6 (913.8) 116.1 (47.4) <. 001
Exerciseisdeﬁnedasasigniﬁcantriseinheartrateformorethan30minutesandatleastonceaweek.Abbreviations:(NS)nonsigniﬁcantparameters,standard
deviation (SD), units (U), cardiovascular disease (CVD), and blood pressure (BP).
comparisons. Second, a repeated measures ANOVA was
used in order to evaluate changes in biomarker levels in
time with groups as a ﬁxed between-subjects factor. Third,
a stepwise discriminant analysis was performed to assess
which biomarkers could best discriminate between the four
study groups. All P-values ≤.05 were considered statistically
signiﬁcant.
3. Results
During followup, no patients were lost for analysis. Only two
patients suﬀered from an acute myocardial infarction during
the followup period: one UAP, one AMI. General patient
characteristics are presented in Table 1. Gender, smoking,
exercise, family history for cardiovascular disease, the use of
beta-blockers, aspirin and statins, creatine kinase, troponin
T, cholesterol and LDL-C levels, and diastolic blood pressure
diﬀered signiﬁcantly between study groups. In addition, it
is known that the concentrations of diﬀerent biomarkers
can be highly dependent on the time between the onset
of symptoms and sample collection [12]. Nonetheless, the
mean time from symptoms to sample collection did not
diﬀer signiﬁcantly in the acute coronary events study groups
(UAP and AMI): 7.8 (range 2.0–10.9) and 6.9 (range 1.2–
11.3) hours, respectively.
Atstudyinclusion,leukocytecountsdiﬀeredsigniﬁcantly
between controls and patients with AMI or UAP (both P<
.001). There was no signiﬁcant diﬀerence between controls
and patients with SAP. In addition, leukocyte counts were
signiﬁcantly higher in patients with AMI than in patients
with UAP (P = .002) or SAP (P<. 001, Figure 1 and
Table 2). There was a signiﬁcant decrease in leukocyte counts
for patients with UAP or AMI after 6-months (P = .011
and P<. 001, resp.), while there were no signiﬁcant changes
in leukocyte counts in patients with SAP or controls. A
signiﬁcantly increased leukocyte count between AMI and
CON remained (P = .002), whereas all other pairwise
comparisons were nonsigniﬁcant (Figure 2).
For ﬁbrinogen, serum concentrations were signiﬁcantly
higher in patients with AMI compared with controls (P =
.002). There was no signiﬁcant diﬀerence between CON and
UAP or SAP, or between AMI and UAP, or between UAP and
SAP (Figure 1 and Table 2). However, there was a trend for a
diﬀerence between AMI and SAP (P = .07). After 6-month
followup, there was only a signiﬁcant decrease in ﬁbrinogen
concentration in patients with AMI (P = .034). There
were no signiﬁcant diﬀerences in ﬁbrinogen concentrations
between diﬀerent study groups at this time point (Figure 2).
ForCRP,therewasasigniﬁcantlyhigherconcentrationin
patients with AMI compared with controls (P = .02). There
was no signiﬁcant diﬀerence between controls and patients
with UAP or SAP, and no signiﬁcant diﬀerences between
A M Ia n dS A Po rU A P ,o rb e t w e e nU A Pa n dS A P( Figure 1,
Table 2). At followup, CRP concentrations were lower in4 International Journal of Vascular Medicine
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Figure 1: Boxplots of biomarkers levels at study inclusion of leukocyte counts (a), ﬁbrinogen (b), CRP (c), myeloperoxidase (d), PAPP-A
(e), and US PAPP-A (f). Statistical diﬀerences are expressed as P<. 05 (∗)o tP ≤ .001 (∗∗).International Journal of Vascular Medicine 5
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Figure 2:Boxplotsofbiomarkerlevelsofleukocytecounts(a),ﬁbrinogen(b),C-reactiveprotein(c),myeloperoxidase(d),andultrasensitive
pregnancy-associated plasma protein A (e) at study inclusion and after 6-month followup. Statistical diﬀerences at 6-month followup were
expressed as P<. 05 (∗)o rP ≤ .001 (∗∗).6 International Journal of Vascular Medicine
Table 2: Pairwise comparisons of serum biomarker level diﬀerences.
Leukocyte count (billions/L) Fibrinogen (g/L)
Group Comp. Mean Δ P-value Group Comp. Mean Δ P-value
CON SAP 0.246 NS CON SAP 0.052 NS
UAP 2.485 <. 001 UAP 0.236 NS
AMI 4.980 <. 001 AMI 0.712 .02
AMI SAP 4.733 <. 001 AMI SAP 0.764 NS
UAP 2.495 .002 UAP 0.476 NS
UAP SAP 2.239 <. 001 UAP SAP 0.288 NS
C-reactive protein (mg/L) Myeloperoxidase (µg/L)
Group Comp. Mean Δ P-value Group Comp. Mean Δ P-value
CON SAP 1.428 NS CON SAP 86.59 NS
UAP 1.408 NS UAP 986.55 <. 001
AMI 9.505 .02 AMI 1375.86 <. 001
AMI SAP 8.077 NS AMI SAP 1462.44 <. 001
UAP 8.097 NS UAP 398.31 NS
UAP SAP 0.020 NS UAP SAP 1073.14 <. 001
PAPP-A (mg/L) US PAPP-A (ng/mL)
Group Comp. Mean Δ P-value Group Comp. Mean Δ P-value
CON SAP 0.080 NS CON SAP 1.288 NS
UAP 0.187 NS UAP 2.123 NS
AMI 0.129 NS AMI 25.527 .001
AMI SAP 0.050 NS AMI SAP 32.885 .001
UAP 0.060 NS UAP 54.200 .001
UAP SAP 0.110 NS UAP SAP 1.648 NS
Pairwise comparisons of diﬀerent biomarker levels between study groups. Abbrevation: not signiﬁcant (NS).
Table 3: Results of diﬀerent discriminant analyses.
Groups (total
number)
Signiﬁcant
biomarkers
Correct classiﬁcation
CON-SAP-
UAP-AMI
(4)
Leukocyte counts,
MPO, PAPP-A US
61.6%
CON/SAP-
UAP-AMI
(3)
Leukocyte counts,
MPO, PAPP-US
82.8%
CON/SAP-
UAP/AMI
(2)
Leukocyte counts,
MPO
89.3%
UAP-AMI (2) Leukocyte counts,
PAPP-A US
82.4%
patients with UAP (P = .009) or AMI (P = .009), and CON
(P = .016). At this time point, there were no signiﬁcant
diﬀerences in CRP concentrations between diﬀerent patient
groups (Figure 2).
ForMPO,serumconcentrationsweresigniﬁcantlyhigher
inpatientswithUAP(P<. 001)orAMI(P<. 001)compared
with controls. There was no signiﬁcant diﬀerence in serum
MPO concentrations between patients with SAP or controls.
Furthermore, serum MPO levels were signiﬁcantly higher in
AMI and UAP compared with SAP (both P<. 001), but
there was no diﬀerence between AMI and UAP (Figure 1 and
Table 2). At followup, the mean MPO concentrations had
signiﬁcantly decreased in patients with SAP (P = .008), UAP
(P<. 001), or AMI (P<. 001) and CON (P<. 001). At 6-
month, MPO concentrations in patients with AMI were still
increased when compared with CON (Figure 2, P = .046).
Finally, for PAPP-A, no signiﬁcant diﬀerences were
demonstrated between the controls and the three groups
of cardiovascular disease for the regular assay kit (Figure 1,
Table 2). Based on these results, we decided not to analyze
serum PAPP-A concentrations in the 6-month followup
blood samples with the regular assay kit. In contrast, the US
PAPP-A kit showed a signiﬁcantly higher concentration of
PAPP-A in AMI when compared with the other study groups
(all P = .001). After 6-month, PAPP-A concentrations of
AMIreturnedtobaselinevalues(P<. 001)andnosigniﬁcant
diﬀerences in PAPP-A concentrations could be observed
between study groups (Figure 2).
A stepwise discriminant analysis was performed to
investigate which combination of the ﬁve biomarkers could
diﬀerentiate between the four groups at study inclusion. In
the stepwise procedure, only leukocyte counts, MPO, and
PAPP-A US emerged as having signiﬁcant discriminative
power. Based on linear combinations of these markers,
subjects could be properly allocated to their speciﬁc groups
in 61.6% (58.6% in the leave-one-out cross-validation) of
the cases (Table 3). Visual inspection of the discriminantInternational Journal of Vascular Medicine 7
functions’ territory map revealed that the centroids of SAP
andCONalmostoverlapped,suggestingsimilarityofproﬁles
as regards their biomarkers’ distributions. This motivated
three subsequent analyses. In the ﬁrst one, SAP and CON
were combined in one group. With this new subdivision (i.e.,
three diagnostic categories), patients’ correct classiﬁcation
improved to 82.8% (cross-validation 80.8%), based on the
same three biomarkers (Table 3). In the second analysis, a
broader dichotomous categorisation of patients in nonacute
coronary events/controls (SAP and CON) versus acute coro-
nary events (UAP and AMI) was considered. Here, patients’
classiﬁcation by leukocyte counts and MPO was correct
in 89.3% of the cases (cross-validation 87.5%, Table 3).
However, PAPP-A US had no further contribution and the
discriminantfunctionswerebasedsolelyonleukocytecounts
and MPO. In contrast, PAPP-A US and leukocyte counts
were the only markers selected in the third analysis, in which
discriminant functions were required to separate between
AMI and UAP patients. In this last analysis, 82.4% of the
acute patients were correctly assigned to their corresponding
groups (cross-validation 80.4%, Table 3).
4. Discussion
In the current study, we evaluated leukocyte counts and
levels of CRP, ﬁbrinogen, MPO, and PAPP-A in patients
with stable (SAP) and unstable angina pectoris (UAP),
acute myocardial infarction (AMI), and healthy controls
(CON). These obtained results showed that inﬂammatory
markers were increased in patients with acute coronary
events (especially myocardial infarction) and were in line
with available literature, which also showed an increase
of these markers after acute coronary events [9, 11, 15].
Followup analysis of these biomarkers after 6-month showed
in general a signiﬁcant decrease in serum concentrations of
these biomarkers in acute coronary syndromes, returning
to concentrations comparable with those of SAP and CON.
However, after six months, leukocyte counts and serum
concentrations of MPO remained signiﬁcantly higher in
patients with AMI when compared with controls. A discrim-
inant analysis showed that of these ﬁve tested biomarkers,
leukocyte counts, MPO, and PAPP-A were most accurate in
predicting study group designation.
Many studies have highlighted the predictive value
of CRP for cardiovascular events. However, large meta-
analyses showed only moderate prognostic value (relative
risk estimates in the range of 1.3 to 1.5) [7, 9]. Similar results
have been published on the use of ﬁbrinogen concentrations
and leukocyte counts for the prediction of cardiovascular
events and outcome (relative risk estimates of 1.4 to 1.8
for ﬁbrinogen and approximately 1.4 for leukocyte counts)
[7, 15, 16]. This creates a need for additional biomarkers for
cardiovascular disease. With this respect, MPO and PAPP-
A have been studied for their potential to serve as novel
biomarkers for cardiovascular disease [11, 13, 17].
MPO has been associated with cardiovascular disease
in many studies [18]. Zhang et al. showed that elevated
serum levels of MPO were associated with coronary artery
disease, as visualized by angiography [19]. These results are
in line with our observations, since we found a signiﬁcant
increase in serum MPO levels in patients with UAP or AMI,
when compared with healthy controls. Additional studies
demonstrated an increased cardiac risk with elevated serum
levels of MPO in patients with acute coronary syndromes,
and an increased odds ratio for major adverse cardiac events
in a cohort of patients presenting with chest pains [11, 20–
22]. Above median plasma, MPO concentrations of AMI
patients were associated with an increased risk for mortality
[23]. In patients with chest pain, MPO proved to be an
independent predictor of AMI on long-term followup [24].
We did not ﬁnd any signiﬁcant diﬀerence in MPO levels
between controls and patients with SAP, which is in contrast
to data published by Ruef et al., that showed an increased
concentration of plasma MPO levels for patients with SAP or
acute coronary syndromes [25]. However, direct comparison
of MPO levels between studies remains diﬃcult, because
many studies diﬀer in their blood sample collection (plasma
or serum) and their laboratory assays to determine MPO
concentrations [18].
Positive immunohistochemical staining for PAPP-A in
advanced atherosclerotic plaques and an elevation of PAPP-
A levels in acute coronary syndromes were shown by Bayes-
Genis et al. [17]. PAPP-A is an independent predictor of
adverse outcome, and elevated levels were associated with
an increased risk for death or myocardial infarction in
patients with acute or stable coronary syndromes [26–28]. In
line with our present ﬁndings, Dominguez-Rodriguez et al.,
applying the regular PAPP-A kit as used in the present study
(DRG International), did not ﬁnd any signiﬁcant diﬀerences
in PAPP-A concentrations between patient with AMI and
controls, and no association between PAPP-A levels and
risk of AMI [29]. However, we currently showed that the
ultrasensitive PAPP-A research kit, using a monoclonal anti-
body speciﬁc for patients with AMI, did show a signiﬁcantly
higher concentration of PAPP-A in AMI when compared
with controls. In healthy controls, PAPP-A is present in
forms complexed with or without the proform of the
eosinophilic major basic protein (proMBP). Uncomplexed
PAPP-A originates from advanced atherosclerotic lesions
[30], and is most likely produced by vascular endothelial and
smooth muscle cells [17]. However, current commercially
availableELISAkits forthedetectionofPAPP-Aaredesigned
to detect Down’s syndrome and therefore focus on the
total amount of PAPP-A present in serum (both complexed
and uncomplexed with proMBP). In order to accurately
assess the association and predictive value of PAPP-A levels
in patients with acute coronary syndromes, the levels of
uncomplexed PAPP-A need to be determined. This might
explain the diﬀerent results that were obtained between
studies with custom made assays and commercially available
assays. Future studies should focus on the association of
thisuncomplexedPAPP-Avariantandcardiovasculardisease
[31]. In the current study, we demonstrated a signiﬁcantly
higher concentration of PAPP-A in AMI when compared
with the other study groups using the ultrasensitive kit. After
6-month, the PAPP-A concentrations of AMI dropped to
baseline values and no diﬀerences in PAPP-A concentrations8 International Journal of Vascular Medicine
between diﬀerent patient groups could be observed. There-
fore, this ultrasensitive PAPP-A kit might aid in the detection
of atherosclerosis-speciﬁc PAPP-A.
Although individual biomarker concentration values
may in average show signiﬁcant increase for cardiovascular
patients, the biomarkers’ variances are generally still rather
higher, resulting in clearly lower biomarker levels in several
aﬀected individuals. Therefore, it is currently believed that
it is unlikely that a single biomarker will be discovered
for predicting cardiovascular events. The general opinion is
shifting towards a multimarker approach, in which a certain
panel of biomarkers is assessed to determine an individual
risk proﬁle of a patient for cardiovascular disease [4, 32]. For
example, Varo et al. demonstrated that patients with elevated
levels of both soluble CD40 ligand and troponin showed a
marked increase in adjusted hazard ratio (HR) for adverse
outcomes (HR 4.3) when compared with soluble CD40
ligand alone (HR 1.9) [33]. Ardigo et al. demonstrated that
a combination of serum levels of multiple chemokines (such
as CCL2, CCL7, CCL8, CCL13, and CXCL10) resulted in a
high degree of accuracy in predicting clinically signiﬁcant
atherosclerotic heart disease in patients with and without
clinically manifest coronary artery disease [34]. In addition,
Wang et al. measured ten diﬀerent biomarkers (CRP, B-type
natriuretic peptide, N-terminal proartrial natriuretic pep-
tide,aldosterone,rennin,ﬁbrinogen,D-dimer,plasminogen-
activator inhibitor-1, homocysteine, and urinary albumin-
to-creatinine-ratio) in 3,209 participants of the Framingham
Heart Study and monitored the participants for a followup
period of 7.4 years [32]. Participants with high multi-
marker levels had a four times increased risk of death and
a twofold increased risk of major cardiovascular events when
compared with participants with low multi-marker levels.
However, it remains unclear which biomarkers should
be included in this panel. With this respect, a stepwise
discriminantanalysisofourdataoftheﬁvetestedbiomarkers
showed that leukocyte counts and MPO were powerful
biomarkers, with regard to the accurate distinction between
patients who had acute coronary events from those who
did not (Table 3). Slightly less accurate but still reasonably
high was the discrimination between AMI, UAP, and a third
group that combined SAP and CON. This time PAPP-A
US contributed signiﬁcantly to the other two biomarkers
(leukocyte counts and MPO). Moreover, within the acute
patients only (i.e., UAP and AMI), PAPP-A US showed a sig-
niﬁcantdiscriminativepower,incombinationwithleukocyte
counts. By contrast, once all four original diagnostic groups
were considered, the classiﬁcation of patients according to
these three biomarkers was suboptimal as only 62% of
the cases were classiﬁed correctly (Table 3). Thus, healthy
controls and patients with SAP share similar biomarkers
proﬁles, indicating that their clear-cut separation would
require additional diagnostic criteria.
These ﬁndings of this discriminant analysis suggest that
of the biomarkers tested in this study, leukocyte counts,
MPO, and PAPP-A US have the most potential as biomarkers
of acute cardiovascular disease and might be suitable can-
didates to be included in the ‘multi-biomarker approach’
to assess the cardiovascular risk. Future studies should
assess the predictive value of this multi-marker approach for
cardiovascular events. We additionally want to emphasize
that the clinical application of a multi-marker approach
depends not only on using the most promising biomarkers,
but also on the ratio between costs and beneﬁts. Therefore,
this should also be taken into account in future studies.
In conclusion, leukocyte counts and levels of ﬁbrinogen,
CRP, myeloperoxidase, and pregnancy associated plasma
protein-A were increased in patients with acute coronary
syndromes. In addition, a discriminant analysis of the ﬁve
biomarkers currently tested showed that leukocyte counts,
MPO, and PAPP-A were most powerful in accurately assess-
ing study group designation, suggesting that this could be
a promising panel for a multi-biomarker approach to assess
cardiovascular risk.
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